Neurohormonal pathway modulation

"Neurohormonal pathway modulation" is not a specific molecule or receptor but rather refers to a therapeutic strategy targeting multiple interacting hormonal signaling systems that regulate cardiovascular function—primarily the renin–angiotensin–aldosterone system (RAAS), sympathetic nervous system (SNS), and natriuretic peptide pathways. These systems play key roles in heart failure pathophysiology by mediating vasoconstriction, sodium/water retention, cardiac remodeling, and maladaptive immune responses. Pharmacological agents such as ACE inhibitors, ARBs, beta-blockers, mineralocorticoid antagonists, and angiotensin receptor-neprilysin inhibitors are used to block or modulate these pathways for clinical benefit in heart failure patients. The term does not refer to a single molecular target but encompasses a class of interventions aimed at restoring balance among these regulatory networks[1][2][3].

Other names

Neurohormonal modulationNeurohormonal pathway modulationNeurohumoral modulation

Drugs act by modulating or blocking neurohormonal pathways such as the renin–angiotensin–aldosterone system, sympathetic nervous system, or enhancing counter-regulatory systems like natriuretic peptides. This results in reduced vasoconstriction, decreased fluid retention, lower cardiac workload, and improved cardiac remodeling*[1][2][5].